ONLINE EXPERT POSTER REVIEW AND DISCUSSION

REPORTING FROM

The 47th Annual Meeting of the European Association for the Study of the Liver (EASL)

JOINTLY SPONSORED BY THE POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALED, LLC.

Alisporivir plus Ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 Phase 2b study

JJ.-M. Pawlotsky, S.K. Sarin, G. Foster, C.-Y. Peng, J. Rasenack, R. Flisiak, T. Piratvisuth, H. Wedemeyer, W.-L. Chuang, W.M. Zhang, N.V. Naoumov

Abstract #1405

Alisporivir in HCV GT 2/3 treatment naive patients: Pase IIb study (Vital-1) study design



Patients stratafied according to viral load and HCV genotype 2 or 3.
* Loading dose: ALV 600mg BID for 1 week; RVR by LOQ (<25 IU/mL) after 4 weeks of treatment; QD=once daily.
RBV = ribavirin 800 mg/day; PegIFN = pegylated interferon α2a 180 µg/week; LOQ=limit of quaritification

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Alisporivir in HCV GT 2/3 treatment naive patients: Pase IIb study (Vital-1) study design



Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Overall SVR 12 for all Treatment Groups (ITT Population)



ITT – interferon-to-treatment population; SVR12 – sustained virological response 12 weeks after treatment end SVR according to limit of quartification (<25 IU/mL); ALV1000=alsporivir; 1000mg QD; ALV600RBV – alisporivir 600mg QD plus ribavirin; ALV800RBV – alisporivir 800mg QD plus ribarvirin; ALV600Peg – alisporivir 600mg QD plus pegylated interferon

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Overall SVR 12 for all Treatment Groups (Per Protocol Population)



Per protocol-patients who completed scheduled 24-week treatment and SVR12 assessment
SVR12 according to limit of quantification (<25 IU/mL)
VB – viral breakthrough

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Antiviral Activity of IFN-Free Alisporivir + Ribavirin Treatment Baseline to Week 6 (ITT Population)



Proportion of Patients with HCV RNA < LOQ

	Week 4	Week 6
ALV100 (n=82)	29%	32%
ALV600RBV(n=84)	37%	49%
ALV800RBV(n=93)	42%	46%

LOQ- limit of qualification (<25IU/mL)

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Incidence of Primary Non-response
(Patients with <1log10 Reduction from Baseline)



Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

Distribution of Patients According to Week 6 HCV RNA Results with IFN-free Alisporivir Treatment (ITT Population)



LOQ- limit of qualification (<25IU/mL)
LOD – limit of detection (10 IU/mL)

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.

On-treatment Response and SVR12 for Patients with RVR Who Continued on Alisporivir Fully IFN-free for 24 Weeks



Per protocol-patients who completed scheduled 24-week treatment and SVR12 assessment
SVR12 according to limit of quartification (<25 IU/mL)
VB – viral breakthrough

Pawlotsky JM, et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1405.